

writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act, including whether the acquisition of the nonbanking company can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 26, 1996.

A. Federal Reserve Bank of Cleveland (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *KeyCorp*, Cleveland, Ohio; to acquire 100 percent of the voting shares of Key Trust Company of Florida, National Association, Winchester, Ohio.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Wildcat, Inc.*, Cedar Rapids, Iowa; to become a bank holding company by acquiring 100 percent of the voting shares of VCR Bancorporation, Ltd., Carlisle, Iowa, and thereby indirectly acquire Hartford-Carlisle Savings Bank, Carlisle, Iowa.

C. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Duncanville Bancshares, Inc.*, Duncanville, Texas; to become a bank holding company by acquiring 100 percent of the voting shares of Duncanville National Bank, Duncanville, Texas.

2. *Unicorp Bancshares - Texas, Inc.*, Orange, Texas; to acquire 100 percent of the voting shares of Unicorp Bancshares - Delaware, Inc., Wilmington, Delaware,

and thereby indirectly acquire First Texas Bank, Vidor, Texas.

In connection with this application Unicorp Bancshares - Delaware, Inc., Wilmington, Delaware, also has applied to acquire 100 percent of the voting shares of First Texas Bank, Vidor, Texas, and 100 percent of the voting shares of OrangeBank, Orange, Texas.

Board of Governors of the Federal Reserve System, March 28, 1996.

William W. Wiles,

*Secretary of the Board.*

[FR Doc. 96-8107 Filed 4-2-96; 8:45 am]

BILLING CODE 6210-01-F

#### **Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities**

The company listed in this notice has given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

The notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 17, 1996.

A. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Texas Bancshares, Inc.*, San Antonio, Texas; to engage *de novo* in the activity of making loans to certain executive officers, directors, affiliates and principal shareholders of Texas Bancshares, Inc., San Antonio, Texas, and the certain executive officers and directors and their related interests of its wholly owned subsidiary banks, First National Bank of South Texas, San Antonio, Texas and The Bank of South Texas, Floresville, Texas, pursuant to § 225.25(b)(1).

Board of Governors of the Federal Reserve System, March 28, 1996.

William W. Wiles,

*Secretary of the Board.*

[FR Doc. 96-8108 Filed 4-2-96; 8:45 am]

BILLING CODE 6210-01-F

#### **Sunshine Act Meeting**

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

**TIME AND DATE:** 11:00 a.m., Monday, April 8, 1996.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

**STATUS:** Closed.

#### **MATTERS TO BE CONSIDERED:**

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

**CONTACT PERSON FOR MORE INFORMATION:** Mr. Joseph R. Coyne, Assistant to the Board; (202) 452-3204. You may call (202) 452-3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: March 29, 1996.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 96-8242 Filed 4-1-96; 10:07 am]

BILLING CODE 6210-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**Centers for Disease Control and Prevention**
**Advisory Committee for Energy-Related Epidemiologic Research, Meeting**

In accordance with section 10(a)(2) of the Federal advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Advisory Committee for Energy-Related Epidemiologic Research.

*Times and Dates:* 9 a.m.-5 p.m., April 18, 1996; 8:30 a.m.-12 noon, April 19, 1996.

*Place:* Inn of the Governors, 234 Don Gaspar, Santa Fe, New Mexico 87501.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* This committee is charged with providing advice and recommendations to the Secretary of Health and Human Services (HHS); the Assistant Secretary for Health; the Director, CDC; and the Administrator, Agency for Toxic Substances and disease Registry (ATSDR), on the establishment of a research agenda and the conduct of a research program pertaining to energy-related analytic epidemiologic studies. The Committee will take into consideration information and proposals provided by the Department of Energy (DOE), the Advisory Committee for Environment Safety and Health which was established by DOE under the guidelines of a Memorandum of Understanding between HHS and DOE, and other agencies and organizations, regarding the direction HHS should take in establishing the research agenda and in the development of a research plan.

*Matters To Be discussed:* Agenda items will include: presentations from the National Center for Environmental Health (NCEH), the National Institute for Occupational Safety and Health, and ATSDR updates on the progress of current studies; discuss working group recommendations, and public involvement activities.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Nadine Dickerson, Program Analyst, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, M/S F-35, Atlanta, Georgia 30341-3724, telephone 770/488-7040, FAX 770/488-7044.

Dated: March 27, 1996.

Nancy C. Hirsch,

*Acting Director, Management Analysis and Services Office, Center for Disease Control and Prevention (CDC).*

[FR Doc. 96-8118 Filed 4-2-96; 8:45 am]

BILLING CODE 4163-18-M

**Food and Drug Administration**

[Docket No. 96C-0097]

**Ethicon, Inc.; Withdrawal of a Color Additive Petition**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a color additive petition (CAP 1C0100) proposing that the color additive regulations be amended to provide for the safe use of D&C Red No. 30 (Talc Lake) in cotton sutures.

**FOR FURTHER INFORMATION CONTACT:** Elke Jensen, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3109.

**SUPPLEMENTARY INFORMATION:** In a notice published in the Federal Register of June 26, 1971 (36 FR 12180), FDA announced that a color additive petition (CAP 1C0100) had been filed by Ethicon, Inc., P.O. Box 151, Somerville, NJ 08876-0151. The petition proposed that 21 CFR part 8, now 21 CFR part 74, of the color additive regulations be amended to provide for the certification and safe use of D&C Red No. 30 (Talc Lake) as a dyeing agent for non-absorbable cotton sutures (USP). Ethicon, Inc., has now withdrawn the petition without prejudice to a future filing (21 CFR 71.6(c)(2)).

Dated: March 26, 1996.

Alan M. Rulis,

*Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 96-8147 Filed 4-2-96; 8:45 am]

BILLING CODE 4160-01-F

**Grassroots Regulatory Partnership Meeting; Southwest Region, Kansas City District Office; Medicated Feed Industry**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of a public meeting.

**SUMMARY:** The Food and Drug Administration (FDA) (Office of External Affairs, Office of Regulatory Affairs, Office of the Southwest Region, and Center for Veterinary Medicine) is announcing a free public meeting as a followup to a meeting held in April 1995. FDA's Kansas City District Office (Southwest Region) and the Center for Veterinary Medicine will meet with interested persons in the Southwest Region to address specific issues related

to the medicated feed industry. The agency is holding this meeting to promote the President's initiative for a partnership approach between front-line regulators and the people affected by the work of the agency.

**DATES:** The public meeting will be held on Tuesday, April 30, 1996, from 8:45 a.m. to 4:10 p.m.

**ADDRESSES:** The public meeting will be held at the Holiday Inn, 6111 Fleur Dr., Des Moines, IA 50321.

**FOR FURTHER INFORMATION CONTACT:** James E. McDonald, FDA Kansas City District Office, P.O. Box 15905, Lenexa, KS 66285-5905, 913-752-2101, FAX 913-752-2111.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of April 20, 1995 (60 FR 19753), FDA announced that a series of Grassroots Regulatory Partnership meetings would be held. Those persons interested in attending this public meeting should FAX their registration including name(s), affiliation, address, telephone and FAX numbers, and any specific questions about the workshop to James E. McDonald (address above), 913-752-2111. There is no registration fee for this meeting. However, due to space limitations, early registration is required. The goal of this meeting is to listen to concerns and ideas, and to identify possible next steps for the agency.

Dated: March 28, 1996.

William K. Hubbard,

*Associate Commissioner for Policy Coordination.*

[FR Doc. 96-8167 Filed 4-2-96; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 96N-0086]

**Medical Device Industry Initiatives**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** FDA is initiating a pilot program in 1996 involving the medical device industry. This pilot program is intended to optimize resource utilization, enhance FDA/industry communication, and provide firms prompt closure to corrected inspectional observations and nonviolative inspections. This pilot program includes eligibility criteria and procedures for preannounced inspections, the annotation of items on form FDA-483-List of Inspectional Observations (FDA 483) with promised or completed corrections, and postinspectional notification to establishments regarding their compliance status.